Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) announced Monday the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational double antibody cocktail for the treatment and prevention of COVID-19.
from RTT - Biotech https://ift.tt/2NXCqmO
via IFTTT
No comments:
Post a Comment